Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced =30% or =5 kPa increases in liver stiffness (LSM) by FibroScan® compared with placebo, indicating slowing of fibrosis progression and stabilization of liver functionAcross all ELF fibrosis risk categories, belapectin 2 mg/kg showed a lower incidence of new varices compared with placebo, with the largest benefit in patients with ELF 11.3 (22.7% vs 42.9%), representing those at highest risk for liver complicationsPro-C3 biomarker analysis demonstrated a 50% reduction from baseline at 18 months with belapectin 2 mg/kg versus placebo, supporting the therapy’s antifibrotic and disease-modifying potential in compensated MASH cirrhosis with portal hypertension.Analysis of YKL-40, a biomarker associated with Galectin-3 upregulation in fibrotic
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business UpdateGlobeNewswire
- Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor ConferenceGlobeNewswire
GALT
Sec Filings
- 12/4/25 - Form 4
- 12/3/25 - Form 8-K
- 11/19/25 - Form 4
- GALT's page on the SEC website